...
首页> 外文期刊>Applied clay science >Synergistic anti-cancer activity of etoposide drug loaded calcium aluminium layered double hydroxide nanoconjugate for possible application in non small cell lung carcinoma
【24h】

Synergistic anti-cancer activity of etoposide drug loaded calcium aluminium layered double hydroxide nanoconjugate for possible application in non small cell lung carcinoma

机译:依托泊苷药物负载的钙铝层状双氢氧化物纳米共轭物的协同抗癌活性可能在非小细胞肺癌中的应用

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The present research reports a facile synthesis of bare phase pure CaAl-LDH nanoparticle (sample A) and intercalation of anti-cancer drug etoposide (ETO) into the same via simple anion exchange technique to obtain ETO loaded CaAl-LDH (sample B). The basal spacing (d(002)) of sample A was increased from 8.5764 angstrom to 17.18 angstrom upon intercalation of ETO. Further ETO loading was found to be 27.72% as estimated by UV-Vis spectrophotometer. The release profile of ETO from sample B in phosphate buffer saline (PBS) at pH 7.4 follows quasi-Fickian diffusion phenomenon in Korsmeyer-Peppas kinetics model. In vitro cell viability was undertaken using A549 (human lung adenocarcinoma) cell line in a dose dependent manner to determine the synergistic anti-cancer potential of sample B. It was observed that at an equivalent dose, the cancer cell viability was substantially reduced, in case of sample B compared to sample A and bare etoposide drug, respectively, which was further corroborated by cell proliferation/migration assay. The cellular uptake using A549 cell line showed an increasing trend with increasing time period (11.67% and 19.30% at 24 h and 72 h) respectively, confirmed by flow cytometry, exhibiting a substantial reduction of CAMKIIa protein for sample A and sample B to 110.52 pg/ml and 95.14 pg/ml respectively. Results also showed significant down regulation of SOD gene activity. All the above results exhibited the synergistic anti-cancer potential of sample B for possible application in the management of non small cell lung carcinoma (NSCLC).
机译:本研究报告通过简单的阴离子交换技术轻松合成裸相纯CaAl-LDH纳米颗粒(样品A),并将抗癌药物依托泊苷(ETO)插入其中,以获得负载ETO的CaAl-LDH(样品B)。 ETO插入后,样品A的基础间距(d(002))从8.5764埃增加到17.18埃。通过UV-Vis分光光度计估计,进一步的ETO负载为27.72%。 ETO在pH 7.4的磷酸盐缓冲盐水(PBS)中从样品B的释放曲线遵循Korsmeyer-Peppas动力学模型中的准Fickian扩散现象。使用A549(人肺腺癌)细胞系以剂量依赖的方式进行体外细胞存活率测定,以确定样品B的协同抗癌潜力。观察到,在等剂量下,癌细胞存活率显着降低。样品B分别与样品A和依托泊苷裸药相比,通过细胞增殖/迁移测定进一步证实了这一点。通过流式细胞术证实,使用A549细胞系的细胞摄取分别随时间的增加而增加(在24 h和72 h分别为11.67%和19.30%),显示样品A和B的CAMKIIa蛋白显着降低至110.52。 pg / ml和95.14 pg / ml。结果还显示SOD基因活性明显下调。以上所有结果显示了样品B的协同抗癌潜力,可能用于非小细胞肺癌(NSCLC)的治疗。

著录项

  • 来源
    《Applied clay science》 |2020年第4期|105496.1-105496.11|共11页
  • 作者

  • 作者单位

    CSIR Bioceram & Coating Div Cent Glass & Ceram Res Inst 196 Raja SC Mullick Rd Kolkata 700032 India;

    Jadavpur Univ Dept Chem Kolkata 700032 India;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    Synergism; Phase pure CaAlLDH nanoparticle; Etoposide; NSCLC;

    机译:协同作用相纯CaAlLDH纳米粒子;依托泊苷;非小细胞肺癌;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号